Get the Stockscreener App
0.6668
1.94%
-0.0132
Hepion Pharmaceuticals Inc stock is traded at $0.6668, with a volume of 37,370.
It is down -1.94% in the last 24 hours and down -18.48% over the past month.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
See More
Previous Close:
$0.68
Open:
$0.59
24h Volume:
37,370
Relative Volume:
0.92
Market Cap:
$3.94M
Revenue:
-
Net Income/Loss:
$-44.68M
P/E Ratio:
-0.0558
EPS:
-11.96
Net Cash Flow:
$-36.70M
1W Performance:
-0.18%
1M Performance:
-18.48%
6M Performance:
-48.71%
1Y Performance:
-78.35%
1-Day Range:
$0.59
$0.6877
1-Week Range:
$0.59
$0.6877
52-Week Range:
$0.5525
$4.47
Hepion Pharmaceuticals Inc Stock (HEPA) Company Profile
Name
Hepion Pharmaceuticals Inc
Sector
Industry
Phone
732-902-4000
Address
399 THORNALL STREET, EDISON
Compare HEPA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| HEPA | 0.6877 | 3.94M | 0 | -44.68M | -36.70M | -11.96 |
| VRTX | 467.34 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 760.66 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 566.22 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 230.69 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.41 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Hepion Pharmaceuticals Inc Stock (HEPA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-20-20 | Resumed | ROTH Capital | Buy |
Hepion Pharmaceuticals Inc Stock (HEPA) Latest News
Hepion Pharmaceuticals Inc (CTVRP) Quarterly 10-Q Report - Quartzy
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger - The Manila Times
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce - GlobeNewswire
Hepion & Pharma Two B Merger Advances: SEC Approves Key Registration for $HEPA Deal | HEPA Stock News - StockTitan
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.67% - MSN
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Statistics, Drugs, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
Will Hepion's AMBITION Be Fulfilled? - RTTNews
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 4% - MarketBeat
Hypha Labs, Inc. Releases Investor Presentation - AccessWire
Does Hyliion Holdings Corporation (NYSE: HYLN) Still Need To Convince Analysts? - Stocks Register
FluoRok raises US$ 9.8million for safety and sustainability of fluorochemical production - Indian Chemical News
FLO stock rated an Underperform by Exane BNP Paribas - Knox Daily
Barrow Hanley Mewhinney & Strauss LLC Purchases Shares of 898,419 Helios Technologies, Inc. (NASDAQ:HLIO) - MarketBeat
Hancock Whitney Corp Buys 10,920 Shares of PHINIA Inc. (NYSE:PHIN) - MarketBeat
FluoRok Raises £7.7M in Funding - FinSMEs
Oxford's FluoRok secures €9.2M from BGF and others - Silicon Canals
HilleVax, Inc. (NASDAQ:HLVX) Given Consensus Rating of “Hold” by Analysts - Defense World
PHINIA Inc. (NYSE:PHIN) Shares Acquired by Long Road Investment Counsel LLC - Defense World
King Luther Capital Management Corp Boosts Position in Helios Technologies, Inc. (NASDAQ:HLIO) - Defense World
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Short Interest Update - Defense World
Hepion Pharmaceuticals faces Nasdaq delisting over share price - Investing.com
Pharma Two B and Hepion Pharmaceuticals file for merger - Investing.com
Pharma Two B and Hepion Pharmaceuticals file for merger By Investing.com - Investing.com UK
Hepion, Pharma Two B file registration statement for proposed merger - TipRanks
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger - ForexTV.com
Hepion Pharmaceuticals (NASDAQ:HEPA) Trading 4.7% Higher - Defense World
TNF Pharmaceuticals (NASDAQ:TNFA) Stock Quotes, Forecast and News Summary - Benzinga
HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q2 2024 - MSN
HEPION PHARMACEUTICALS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
GSK, Novartis lead July deals as biopharma sector sees more than $20B for the month - BioWorld Online
Hepion Pharmaceuticals announces executive leadership changes - Investing.com India
Hepion Pharmaceuticals announces executive leadership changes By Investing.com - Investing.com UK
Following restructuring, Hepion to merge with Israeli pharma firm - NJBIZ
Cingulate (NASDAQ:CING) Stock Quotes, Forecast and News Summary - Benzinga
HEPA hits 52-week low, trading at 0.7324 USD - Investing.com
HEPA hits 52-week low, trading at 0.7324 USD By Investing.com - Investing.com Canada
Oligonucleotide Therapy Market Targeting the Future of Medicine: Oligonucleotide Therapies Offer Precision ... - WhaTech
Financial Health Check: Examining Hepion Pharmaceuticals Inc (HEPA)’s Key Ratios - The Dwinnex
Aurora Innovation Inc [AUR] Is Currently -0.71 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Oligonucleotide Therapy Market to Reach USD 19.92 Billion by 2031 | InsightAce Analytic - openPR
The Globe and Mail - The Globe and Mail
Oligonucleotide Therapy Market Transforming Healthcare: - openPR
Hepion Pharmaceuticals Inc’s Banking’s 100-Day Moving Average at 1.6118: Will the Stock Break Through? - The InvestChronicle
The Hepion Pharmaceuticals Inc (HEPA) Stock Is Headed for a Correction - US Post News
IQVIA 'Is A Solid Investment' With Strong Competitive Positioning, Analyst Says After Better Than Expected Q2 Earnings - Markets Insider
Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer - Benzinga
Hepion Pharmaceuticals’ Strategic Merger and Corporate Restructuring - TipRanks
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement - StockTitan
HEPAHepion Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Hepion Pharmaceuticals (NASDAQ:HEPA) Stock Quotes, Forecast and News Summary - Benzinga
Biogen Inc. to Post Q2 2024 Earnings of $4.12 Per Share, Leerink Partnrs Forecasts (NASDAQ:BIIB) - American Banking and Market News
Hepion Pharmaceuticals Inc Stock (HEPA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Hepion Pharmaceuticals Inc Stock (HEPA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wijngaard Peter | Director |
Nov 27 '23 |
Buy |
3.05 |
2,500 |
7,625 |
9,501 |
3.39%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):